Analyst Price Targets — MNPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 30, 2026 10:04 am | — | BTIG | $117.00 | $94.56 | StreetInsider | Monopar Therapeutics (MNPR) PT Raised to $117 at BTIGMember Login |
| June 29, 2026 11:08 am | — | UBS | $105.00 | $87.68 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR) |
| June 2, 2026 10:58 am | — | Piper Sandler | $105.00 | $64.40 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR) |
| January 9, 2026 10:11 am | Maxwell Skor | Morgan Stanley | $115.00 | $63.40 | TheFly | Monopar Therapeutics initiated with an Overweight at Morgan Stanley |
| November 14, 2025 10:06 am | Chris Raymond | Raymond James | $123.00 | $87.01 | StreetInsider | Raymond James Downgrades Monopar Therapeutics (MNPR) to Outperform |
| October 13, 2025 9:25 am | Etzer Darout | Barclays | $125.00 | $87.82 | TheFly | Monopar Therapeutics initiated with an Overweight at Barclays |
| October 6, 2025 11:26 am | — | Raymond James | $142.00 | $99.39 | TheFly | Monopar Therapeutics price target raised to $142 from $80 at Raymond James |
| October 2, 2025 11:50 am | — | Oppenheimer | $115.00 | $84.73 | TheFly | Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer |
| September 29, 2025 12:13 pm | — | H.C. Wainwright | $105.00 | $76.63 | TheFly | Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright |
| September 25, 2025 11:55 am | Keay Nakae | Chardan Capital | $85.00 | $72.70 | TheFly | Monopar Therapeutics price target raised to $85 from $60 at Chardan |
Latest News for MNPR
Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. ALXN1840 is their Wilson disease asset, which currently has a much clearer regulatory path, FDA designations, and even a possible Priority Review Voucher. MNPR's financing also seems safer this time around as they prepare ALXN1840's NDA and subsequent potential launch.
WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company's late-stage…
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the…
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation (link) of Phase 2 ALXN1840-WD-205 data at the European Association for the Study of the Liver (EASL) Congress 2026. In a presentation titled “ALXN1840…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MNPR.
U.S. House Trading
No House trades found for MNPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.